Recent advances in clinical passive immunotherapy have provided compelling evidence
that eliminating amyloid-β (Aβ) slows cognitive decline in Alzheimer's disease (AD) …

For the treatment of neurological diseases, achieving sufficient exposure to the brain
parenchyma is a critical determinant of drug efficacy. The blood–brain barrier (BBB) …

The protein alpha-synuclein (αSYN) plays a central role in synucleinopathies such as
Parkinsons's disease (PD) and multiple system atrophy (MSA). Presently, there are no …

Immunotherapy targeting aggregated alpha-synuclein (αSYN) is a promising approach for
the treatment of Parkinson's disease. However, brain penetration of antibodies is hampered …

The interest for developing antibody‐driven therapeutic interventions has exponentially
grown over the last few decades. Even though there have been promising leaps in the …

Background Hijacking the transferrin receptor (TfR) is an effective strategy to transport
amyloid-beta (Aβ) immuno-positron emission tomography (immunoPET) ligands across the …

Pretargeting is a promising nuclear imaging technique that allows for the usage of
antibodies (Abs) with enhanced imaging contrast and reduced patient radiation burden. It is …

Background Aggregation of the amyloid-β (Aβ) peptide in the brain is one of the key
pathological events in Alzheimer's disease (AD). Reducing Aβ levels in the brain by …

The blood-brain barrier (BBB) is a protective and semipermeable border of endothelial cells
that prevents toxins and foreign bodies to enter and damage the brain. Unfortunately, the …

Background Brain-directed immunotherapy is a promising strategy to target amyloid-β (Aβ)
deposits in Alzheimer's disease (AD). In the present study, we compared the therapeutic …